(NASDAQ:HSDT) shares are up 60% on 62,00 trades at $2.39

Helius Medical Announces Poster to Be Presented at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Conference M2 Communications “ENP Newswire”

NEWTOWN, Pa. – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (‘Helius’ or the ‘Company’), a neurotech company focused on neurological wellness, announced that an abstract highlighting real-world data, which shows the impact of translingual neurostimulation as a rehabilitation therapy to improve gait in people with multiple sclerosis (MS), has been selected for a poster presentation at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Meeting taking place June 1-4 in National Harbor , Maryland .

‘We are excited to share our real-world findings on neuromodulation to improve MS patients’ ability to walk steadily and safely,’ said Antonella Favit-Van Pelt , MD, PhD, Helius Medical’s Chief Medical Officer. ‘Our findings show that neuromodulation stimulation is an effective rehabilitative intervention that is thought to engage mechanisms of upregulation and long-term potentiation, promoting neuroplasticity and improving gait functionality and mobility.’

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.